Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
141.00
0.00 (0.00%)
At close: Jul 9, 2026
TPEX:3218 Revenue
Universal Vision Biotechnology had revenue of 1.09B TWD in the quarter ending March 31, 2026, a decrease of -2.97%. This brings the company's revenue in the last twelve months to 4.17B, down -2.56% year-over-year. In the year 2025, Universal Vision Biotechnology had annual revenue of 4.20B, down -0.57%.
Revenue (ttm)
4.17B
Revenue Growth
-2.56%
P/S Ratio
2.86
Revenue / Employee
10.40M
Employees
401
Market Cap
11.95B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.20B | -24.22M | -0.57% |
| Dec 31, 2024 | 4.23B | 146.05M | 3.58% |
| Dec 31, 2023 | 4.08B | 588.20M | 16.83% |
| Dec 31, 2022 | 3.49B | 862.26M | 32.76% |
| Dec 31, 2021 | 2.63B | 578.66M | 28.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Great Tree Pharmacy | 19.07B |
| PharmaEssentia | 17.50B |
| Standard Chemical & Pharmaceutical | 7.03B |
| TaiDoc Technology | 4.30B |
| Vizionfocus | 3.71B |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |
| ACRO Biomedical | 38.26M |